Life Science Company Finances
Life Science Company Finances explores the funding landscape and R&D dynamics within the pharmaceutical and biotech sectors. Since the 1980s, these industries have seen increased R&D investment, with innovation shifting towards smaller companies and academic institutions. The Orphan Drug Act has fueled rare disease research, especially through high-value gene therapies attractive to smaller entities. The drug development process often begins in universities with NIH funding and involves complex licensing. Early financing comes from grants and angel investors, while venture capital, convertible debt, and strategic partnerships drive later stages. IPOs, reverse mergers, and SPACs provide public market access, highlighting the essential role of institutional investor support.
Non-CPE Credit
CPE Credit
Section 1
Learn about the shifting landscape of pharmaceutical and biotech research and development, from the rise of orphan drug development to the role of academic institutions in fueling innovation.
Section 2
Learn about the key insights and trends in the life sciences industry, including the challenges of academic licensing, financing sources for early-stage biotechs, and the dynamics of late-stage deals.
Section 3
Learn about the key financing sources and strategies for biotech startups, including grants, equity investments, convertible debt, and public market access through IPOs and SPACs.
Five Takeaways
- Develop a comprehensive understanding of DNA, RNA,
and proteins in the context of biotechnology. - Understand the role of academic research—often NIH-funded—as the foundation of most new
drug development candidates, though licensing from universities remains challenging due to inefficiencies. - Gain insights into the critical role of equity financing, especially from venture capital firms, in supporting the costly biotech drug development process, with convertible debt and preferred stock being common financing tools.
- Explore the importance of strategic partnerships and access to public markets, including IPOs, reverse mergers, and SPACs, which provide validation and essential financing options for biotech companies.
- Identify the need for biotech startups to secure institutional investor support, given the relatively small, interconnected life sciences venture capital community, to advance their drug development programs.
Features
- Closed Captioning in English, Spanish, French, French Canadian, Hindi, Japanese, Korean, Mandarin, Russian, Standard Arabic
- Transcripts in English, Spanish, French, French Canadian, Hindi, Japanese, Korean, Mandarin, Russian, Standard Arabic
- Course materials
- Real-time tracking
- Progress reporting
- Accessibility features
- Corporate account upgrades
- LinkedIn certificate attachment
- Verified certificates
Upgrade to CPE Credits!
Make your training count by achieving Continuing Professional Education Credits.